

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

06 June 2019 (06.06.2019)



(10) International Publication Number

WO 2019/106377 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/444 (2006.01)
A61P 3/10 (2006.01)

(21) International Application Number:

PCT/GB2018/053466

(22) International Filing Date:

29 November 2018 (29.11.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1719881.3 29 November 2017 (29.11.2017) GB
62/592,140 29 November 2017 (29.11.2017) US

(71) Applicant: **KALVISTA PHARMACEUTICALS LIMITED** [GB/GB]; Porton Science Park, Bybrook Road, Porton Down, Salisbury SP4 0BF (GB).

(72) Inventors: **CROWE, David Malcolm**; Pharmaterials Ltd, 5, Boulton Road, Reading RG2 0NH (GB). **MACDONALD-BROWN, Stephen Mark**; Charnwood Molecular Ltd, The Heritage Building, 7 Beaumont Court, Prince William Road, Loughborough LE11 5DA (GB). **ARET, Edwin**; Alcam Corporation, Vliesvenweg 1, 6002 NM Weert (NL). **GHANDI, Kiran**; Johnson Matthey Plc, Pharmorphix Solid State Services, 250 Cambridge Science Park, Milton Road, Cambridge CB4 0WE (GB). **LELIEVELD, Ruben Henricus Carolus Adrianus Titus**; Alcam Corporation, Vliesvenweg 1, 6002 NM Weert (NL). **SHARP, Emma Kay**; Johnson Matthew Plc, Pharmorphix Solid State Services, 250 Cambridge Science Park, Milton Road, Cambridge CB4 0WE (GB). **TODD, Richard Simon**; Kalvista Pharmaceuticals Limited, Porton Science Park, Bybrook Road, Porton Down, Salisbury SP4 0BF (GB).

(74) Agent: **MCGUIRE, Gillian Margaret** et al.; Carpmals & Ransford LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF

(57) Abstract: New solid forms of the plasma kallikrein inhibitor, 1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl)methyl)-N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)pyrazole-4-carboxamide and its salts, are described.

WO 2019/106377 A1